KR920021522A - 피페라진 유도체 - Google Patents
피페라진 유도체 Download PDFInfo
- Publication number
- KR920021522A KR920021522A KR1019920007528A KR920007528A KR920021522A KR 920021522 A KR920021522 A KR 920021522A KR 1019920007528 A KR1019920007528 A KR 1019920007528A KR 920007528 A KR920007528 A KR 920007528A KR 920021522 A KR920021522 A KR 920021522A
- Authority
- KR
- South Korea
- Prior art keywords
- ethyl
- cyclohexanecarboxamide
- methoxyphenyl
- pyridyl
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, ***e
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
- Bending Of Plates, Rods, And Pipes (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (2)
- 다음 일반식(Ⅰ)의 화합물 또는 약제학적으로 허용되는 이의 산 부가염.상기 식에서, A는 하나 이상의 저급 알킬 그룹에 의해 임의로 치환되는 탄소수 2 내지 4의 알킬렌쇄이고, Z는 산소 또는 황이며, R은 수소 또는 저급 알킬이고, R1은 모노 또는 비사이클릭 아릴 또는 헤테로아릴 라디탈이며, R2는 모노 또는 비사이클릭 헤테로아릴 라디칼이고, R3은 수소 저급 알킬, 사이클로알킬, 사이클로알케닐, 사이클로알킬(저급)알킬, 아릴, 아릴(저급)알킬, 헤테로아릴, 헤테로아릴(저급)알킬, 일반식 -NR4R5의 그룹[여기서, R4는 수소, 저급 알킬, 아릴 또는 아릴(저급)알킬이고. R5는 수소, 저급 알킬, -CO(저급)알킬, 아릴, CO아릴, 아릴(저급)알킬, 사이클로알킬 또는 사이클로알킬-(저급)알킬이거나, 또는 R4및 R5는 이들이 결합하고 있는 질소원자와 함께 추가의 헤테로 원자를 함유할 수도 있는 포화 헤테로사이클릭 환을 형성한다]또는 일반식 OR6의 그룹[여기서, R6은 저급 알킬, 사아클로알킬, 사이클로알킬(저급)알킬, 아릴, 아릴(저급)알킬, 헤테로아릴 또는 헤테로아릴(저급)알킬이다.]이다.
- 제1항에 있어서, N-(2-(1-(4-(2-메톡시페닐)-피페라지닐))에틸)-N-(2-피리디닐)사이클로헥산카복스아미드 또는 N-사이클로헥실-N′-(2-(1-(4-(2-메톡시페닐)-피페라지닐))에틸)-N-(2-피리디닐)우레아 또는 N-(2-(1-(4-(2-메톡시페닐)-피페라지닐))에틸)-N-(2-피리디닐)벤즈아미드 또는 N-(2-(1-(4-(2-메톡시페닐)-피페라지닐))에틸)-N-(2-티아졸릴)트리메틸아세트아미드 또는 N-(2-(1-(4-(2-메톡시페닐)-피페라지닐))에틸)-N-(2-티아졸릴)사이클로헥산카복스아미드 또는 N-(2-(4-(4-플로오로-2-메톡시페닐)-피페라지닐))에틸)-N-(2-피리디닐)사이클로헥산카복스 아미드 또는 N-(2-(1-(4-(2,3-디하이드로-1,4-벤조디옥신-5-일)-피페라지닐))에틸)-N-(2-피리디닐)사이클로헥산카복스 아미드 또는 N-[2-[1-[4-[3-(1,2-벤즈이소티아졸일)]]피페라지닐))에틸)-N-(2-피리디닐)사이클로헥산카복스아미스 또는 N-(2-(1-(4-(2-메톡시페닐)피페리지닐))에틸)-N-(1-피페리디닐카보닐)-2-피리딘 또는 N-(2-(1-(4-(2-메톡시페닐)피페리지닐))에틸)-N-(피리딘-2-일)-N′-사이클로헥실티오우레아 또는 N-(2-(1-(4-(2-하이드록시페닐)-1-피레라지닐))에틸)-N-(2-피리딜)사이클로헥산카복스아미드 또는 N-(2-(1-(4-(1-나프틸))피레라지닐)에틸)-N-(2피리딜)사이클로헥산카복스아미드 또는 N-(2-(1-(4-(2-메틸페닐))피페라지닐)에틸)-N-(2-피리딜)사이클로헥산카복스아미드 또는 N-[2[1-[4-(2-플우오르페닐))피페라지닐)에틸)-N-(2-피리딜)사이클로헥산카복스아미드 또는 N-[2[1-[4-(1-이소퀴놀리닐)]피페라지닐))에틸)-N-(2-피리디닐)사이클로헥산카복스아미드 또는 N-[2-[1-[4-1(7-메톡시)나프틸]]피레라지닐))에틸)-N-(2-피리디닐)사이클로헥산카복스아미드 또는 N-(2-(1-(4-(2-메톡시페닐)피페리지닐))에틸)-N-(2-피리딜)아다만탄-1-카복시아미드 또는 N-[2[1-[4-(1-(7-메톡시)나프틸]]피레라지닐))에틸)-N-(2-피리디닐)사이클로헥산카복스아미드 또는 N-[2[1-[4-(1-(5,6,7,8-테트라하이드로)나트틸]]-페라지닐]에틸0-N-[(2-피리디닐)사이클로헥산카복스아미드 또는 (S)-N-(1-메틸-2-(4-(2-메톡시페닐)-1-피레라지닐)에틸)-N-(2-피리딜)사이클로헥산카복스아미드 또는 (R)-N-(1-메틸-2-(4-(2-메톡시페닐)-1-피레라지닐)에틸)-N-(2-피리딜)사이클로헥산카복스아미드 또는 N-[3-[4-(2-메톡시페닐)-1-페리지닐]프로필)-N-[(2-피리딜)사이클로헥산카복스아미드 또는 N-[2-[4-(2-메톡시페닐)-1-페라지닐]에틸)-N-(2-퀴놀리닐)사이클로헥산카복스아미드 또는 (Rac)-N-(2-(4-(2-메톡시페닐)-1-페라지닐)프로필)-N-(2-피리딜)사이클로헥산카복스아미드 또는 (S)-N-(2-(4-(2-메톡시페닐)-1-피레라지닐)에틸)-N-(2-피리딜)사이클로헥산카복스아미드 또는 (R)-N-(2-(4-(2-메톡시페닐)-1-피레라지닐)에틸)-N-(2-피리딜)사이클로헥산카복스아미드 또는 N-(2-(4-페닐-1-피페리지닐)에틸)-N-(2-피리딜)사이클로헥산카복스아미드 또는 N-2-(4-(2-이소프로필페닐)-1-(피레라지닐)에틸)-N-(2-피리딜)사이클로헥산카복스아미드 또는 N-(2-(4-(2-메톡시페닐)-1-피페라지닐)에틸)-N-(4-피리딜)사이클로헥산카복스아미드 또는 N-(2-(4-(2-메톡시페닐)-1-(피페라지닐)에틸)-N-(3-피리딜)사이클로헥산카복스아미드 또는 N-(2-(4-(2-메톡시페닐)피레라진-1-일)에틸)-N-(2-피리디닐)사이클로헥스-1-엔카복스아미드 또는 N-(2-(4-(2-메톡시페닐)-1-(피페라지닐)에틸)-N-(2-피리디닐)사이클로헥산카복스아미드인 화합물 또는 약제학적으로 허용되는 의의 염.※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB919109475A GB9109475D0 (en) | 1991-05-02 | 1991-05-02 | Piperazine derivatives |
GB9109475.5 | 1991-05-02 | ||
GB9127189 | 1991-12-21 | ||
GB919127189A GB9127189D0 (en) | 1991-12-21 | 1991-12-21 | Piperazine derivatives |
GB9127189.0 | 1991-12-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR920021522A true KR920021522A (ko) | 1992-12-18 |
KR100203254B1 KR100203254B1 (ko) | 1999-06-15 |
Family
ID=26298819
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019920007528A KR100203254B1 (ko) | 1991-05-02 | 1992-05-02 | 피페라진 유도체 |
Country Status (24)
Country | Link |
---|---|
US (1) | US6127357A (ko) |
EP (1) | EP0512755B1 (ko) |
JP (1) | JP3095521B2 (ko) |
KR (1) | KR100203254B1 (ko) |
CN (2) | CN1040106C (ko) |
AT (1) | ATE115566T1 (ko) |
AU (1) | AU645681B2 (ko) |
BR (1) | BR9201624A (ko) |
CA (1) | CA2067929C (ko) |
CZ (1) | CZ286778B6 (ko) |
DE (1) | DE69200893T2 (ko) |
DK (1) | DK0512755T3 (ko) |
ES (1) | ES2065133T3 (ko) |
FI (1) | FI108720B (ko) |
GB (1) | GB2255337B (ko) |
HK (1) | HK1003001A1 (ko) |
HU (2) | HU223527B1 (ko) |
IE (1) | IE64634B1 (ko) |
IL (1) | IL101722A (ko) |
MX (1) | MX9201991A (ko) |
MY (1) | MY107756A (ko) |
RU (1) | RU2193561C2 (ko) |
SK (1) | SK280133B6 (ko) |
UA (1) | UA39917C2 (ko) |
Families Citing this family (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU645681B2 (en) * | 1991-05-02 | 1994-01-20 | John Wyeth & Brother Limited | Piperazine derivatives |
GB9223153D0 (en) * | 1992-11-05 | 1992-12-16 | Wyeth John & Brother Ltd | Piperazine derivatives |
GB9300195D0 (en) * | 1993-01-06 | 1993-03-03 | Wyeth John & Brother Ltd | Piperazine derivatives |
GB9302622D0 (en) * | 1993-02-10 | 1993-03-24 | Wellcome Found | Heteroaromatic compounds |
GB9303968D0 (en) * | 1993-02-26 | 1993-04-14 | Wyeth John & Brother Ltd | 5-ht1a ligands |
GB9305672D0 (en) * | 1993-03-19 | 1993-05-05 | Wyeth John & Brother Ltd | Amide derivatives |
GB9306103D0 (en) * | 1993-03-24 | 1993-05-12 | Wyeth John & Brother Ltd | Piperazine derivatives |
FR2707294B1 (fr) * | 1993-07-06 | 1995-09-29 | Pf Medicament | Nouveaux dérivés de la 3,5-dioxo-(2H,4H)-1,2,4-triazine, leur préparation et leur application en thérapeutique humaine. |
GB9314758D0 (en) * | 1993-07-16 | 1993-08-25 | Wyeth John & Brother Ltd | Heterocyclic derivatives |
US5609849A (en) * | 1994-03-11 | 1997-03-11 | The Trustees Of The University Of Pennsylvania | Serotonin (5-HT1A) receptor ligands and imaging agents |
GB9411099D0 (en) * | 1994-06-03 | 1994-07-27 | Wyeth John & Brother Ltd | Piperazine derivatives |
PT763024E (pt) * | 1994-06-03 | 2002-11-29 | Wyeth John & Brother Ltd | Novos processos e intermediarios para a preparacao de derivados de piperazina |
DE4425146A1 (de) * | 1994-07-15 | 1996-01-18 | Basf Ag | Verwendung heterocyclischer Verbindungen |
US6231833B1 (en) | 1999-08-05 | 2001-05-15 | Pfizer Inc | 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors |
EP0714663A3 (en) | 1994-11-28 | 1997-01-15 | Lilly Co Eli | Potentiation of drug responses by serotonin 1A receptor antagonists |
FR2727682A1 (fr) * | 1994-12-02 | 1996-06-07 | Pf Medicament | Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament |
US5541179A (en) * | 1995-05-02 | 1996-07-30 | American Home Products Corporation | Tropon-2-one piperazine carboxamides as serotonergic agents |
GB9514901D0 (en) * | 1995-07-20 | 1995-09-20 | American Home Prod | Piperazine derivatives |
ES2145977T3 (es) * | 1995-08-16 | 2000-07-16 | Lilly Co Eli | Potenciacion de la respuesta de la serotonina. |
GB9525239D0 (en) * | 1995-12-09 | 1996-02-07 | American Home Prod | Medical treatment |
US5990114A (en) * | 1996-02-28 | 1999-11-23 | Recordati, S.A., Chemical And Pharmaceutical Company | Use of 5-HT1A receptor antagonists for the treatment of urinary incontinence |
IT1282705B1 (it) * | 1996-02-28 | 1998-03-31 | Recordati Chem Pharm | Uso di antagonisti del recettore serotoninergico 5-ht|a per il trattamento dell'incontinenza urinaria |
DE19615232A1 (de) * | 1996-04-18 | 1997-10-23 | Merck Patent Gmbh | Neue Carbamoylderivate und deren Verwendung als 5-HT ¶1¶¶A¶-Antagonisten |
FR2753968B1 (fr) * | 1996-09-27 | 1998-11-27 | Sod Conseils Rech Applic | Nouvelles heteroaryloxyethylamines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant |
FR2756283A1 (fr) * | 1996-11-27 | 1998-05-29 | Pf Medicament | Amines aromatiques d'arylpiperazines, leur preparation et leurs applications comme medicaments |
NZ337183A (en) * | 1997-03-04 | 2001-05-25 | Neurogen Corp | 1-(isoquinolin-1-yl)-4-(1-phenylmethyl)piperazines; dopamine receptor subtype specific ligands useful for the treatment of psychotic disorders |
US6008352A (en) * | 1997-04-03 | 1999-12-28 | Neurogen Corporation | 1-(isoquinolin-1-yl)-4-(1-phenylmethyl) piperazines; dopamine receptor subtype specific ligands |
US6313141B1 (en) | 1997-06-13 | 2001-11-06 | Neurogen Corporation | 2-aminoalkylaminoquinolines as dopamine D4 ligands |
US5972945A (en) * | 1997-06-13 | 1999-10-26 | Neurogen Corporation | 2-aminoalkylaminoquinolines; dopamine receptor subtype specific ligands |
EP0991642A1 (en) * | 1997-06-13 | 2000-04-12 | Neurogen Corporation | 2-aminoalkylaminoquinolines as dopamine d4 ligands |
US6399614B1 (en) | 1997-08-01 | 2002-06-04 | Recordati S.A. Chemical And Pharmaceutical Company | 1-(N-phenylaminoalkyl)piperazine derivatives substituted at position 2 of the phenyl ring |
IT1293804B1 (it) | 1997-08-01 | 1999-03-10 | Recordati Chem Pharm | Diarilalchilpiperazine attive sulle basse vie urinarie |
US6271234B1 (en) * | 1997-08-01 | 2001-08-07 | Recordati S.A., Chemical And Pharmaceutical Company | 1,4-disubstituted piperazines |
JP2001512110A (ja) * | 1997-08-01 | 2001-08-21 | レコルダチ エッセ.ア.,ケミカル アンド ファーマシューティカル カンパニー | 1,4−ジ置換ピペラジン |
EP0900792B1 (en) * | 1997-09-02 | 2003-10-29 | Duphar International Research B.V | Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists |
ATE253058T1 (de) | 1997-09-02 | 2003-11-15 | Duphar Int Res | Piperidin- und piperazin derivate als 5-ht1- rezeptor-agonisten |
UA66370C2 (en) | 1997-12-16 | 2004-05-17 | Lilly Co Eli | Arylpiperazines having activity to setotonin 1 receptors |
US6281216B1 (en) | 1998-02-09 | 2001-08-28 | Duphar International Research B.V. | 2-aminoquinoline derivatives having d4-agonistic activity |
EP1087954A1 (en) * | 1998-06-15 | 2001-04-04 | American Home Products Corporation | Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents |
US6376494B1 (en) | 1998-06-15 | 2002-04-23 | American Home Products Corporation | Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents |
US6344458B1 (en) | 1998-12-17 | 2002-02-05 | American Home Products Corporation | Piperazine ethylamide derivatives |
JP2002532481A (ja) * | 1998-12-17 | 2002-10-02 | アメリカン・ホーム・プロダクツ・コーポレイション | 5−ht1a受容体活性を有するピペラジンエチルアミド誘導体 |
BR0015539A (pt) | 1999-11-12 | 2002-07-16 | Wyeth Corp | Adamantil e noradamantil aril- e aralquilpiperazinas ramificadas com atividade 5-ht1a de serotonina |
US6831084B1 (en) | 1999-11-12 | 2004-12-14 | Wyeth | Branched adamantyl and noradamantyl aryl- and aralkylpiperazines with serotonin 5-HT1A activity |
KR100333500B1 (ko) * | 2000-01-19 | 2002-04-25 | 박호군 | 아릴피페라진 화합물 및 그의 제조방법 |
US6613901B2 (en) | 2000-03-08 | 2003-09-02 | Neurogen Corporation | 2-aminoalkylaminoquinolines as dopamine D4 ligands |
US6469007B2 (en) | 2000-11-28 | 2002-10-22 | Wyeth | Serotonergic agents |
US20060223824A1 (en) * | 2000-11-28 | 2006-10-05 | Wyeth | Serotonergic agents |
US20060287335A1 (en) | 2000-11-28 | 2006-12-21 | Wyeth | Serotonergic agents for treating sexual dysfunction |
EP1408976B3 (en) | 2001-07-20 | 2010-08-25 | Psychogenics Inc. | Treatment for attention-deficit hyperactivity disorder |
US6974869B2 (en) * | 2001-09-18 | 2005-12-13 | Bristol-Myers Squibb Pharma Company | Piperizinones as modulators of chemokine receptor activity |
ES2283762T3 (es) * | 2002-03-12 | 2007-11-01 | Wyeth | Preparacion de acido n1-(2'-piridil)-1,2-propanodiaminosulfamico y su uso en la sintesis de piperazinas biologicamente activas. |
RU2315762C2 (ru) * | 2002-03-12 | 2008-01-27 | Уайт | Способ синтеза хиральных n-арилпиперазинов |
US7091349B2 (en) | 2002-03-12 | 2006-08-15 | Wyeth | Process for synthesizing N-aryl piperazines with chiral N′-1-[benzoyl(2-pyridyl)amino]-2-propane substitution |
US7361773B2 (en) * | 2002-03-12 | 2008-04-22 | Wyeth | Preparation of N1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines |
AU2003220110B2 (en) | 2002-03-12 | 2009-04-09 | Wyeth | Process for making chiral 1,4-disubstituted piperazines |
WO2003099266A2 (en) * | 2002-05-23 | 2003-12-04 | Abbott Laboratories | Acetamides and benzamides that are useful in treating sexual dysfunction |
BR0314393A (pt) * | 2002-09-17 | 2005-07-19 | Warner Lambert Co | Piperazinas heterocìclicas substituìdas para o tratamento de esquizofrenia |
WO2004041793A1 (en) * | 2002-11-08 | 2004-05-21 | Warner-Lambert Company Llc | Phenylalkyl and pyridylalkyl piperazine derivatives |
US7179813B2 (en) | 2003-06-11 | 2007-02-20 | Wyeth | Bicyclic indolyl derivatives and methods for their use as serotonergic agents |
US7160888B2 (en) * | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
JP2007513197A (ja) * | 2003-12-08 | 2007-05-24 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 統合失調症の治療のための複素環式置換インダン誘導体および関連化合物 |
US20050165025A1 (en) * | 2004-01-22 | 2005-07-28 | Recordati Ireland Ltd. | Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists |
US20070099931A1 (en) * | 2004-03-19 | 2007-05-03 | Wyeth | Pharmaceutical dosage forms and compositions |
US20050215561A1 (en) * | 2004-03-19 | 2005-09-29 | Krishnendu Ghosh | Pharmaceutical dosage forms and compositions |
US20050209245A1 (en) * | 2004-03-19 | 2005-09-22 | Wyeth | Process for preparing N-aryl-piperazine derivatives |
JP2008512086A (ja) * | 2004-06-04 | 2008-04-24 | ワイス | 喘息治療薬としてのRegIII蛋白質の阻害物質 |
EP1817269B1 (en) * | 2004-11-05 | 2013-01-02 | GE Healthcare Limited | Use of [11c] carbon monoxide in labeling synthesis of 11c-labelled amides using photo-induced free radical carbonylation |
TW200700413A (en) * | 2005-03-01 | 2007-01-01 | Wyeth Corp | Crystalline and amorphous 4-cyano-n-{(2r)-2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazin-1-yl]-propyl}-n-pyridin-2-yl-benzamide hydrochloride |
JP4109709B1 (ja) * | 2005-04-01 | 2008-07-02 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 統合失調症の治療のためのテトラヒドロ−ピリドアゼピン−8−オン及び関連化合物 |
TW200800959A (en) * | 2005-06-10 | 2008-01-01 | Wyeth Corp | Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor |
MX2007015772A (es) * | 2005-06-17 | 2008-02-22 | Wyeth Corp | Compuestos utiles como inhibidores de serotonina y agonistas y antagonistas de 5-ht-1a. |
US7731940B2 (en) | 2006-01-25 | 2010-06-08 | The Regents Of The University Of California | Compositions and methods related to serotonin 5-HT1A receptors |
TW200811144A (en) * | 2006-06-09 | 2008-03-01 | Wyeth Corp | Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline |
TW200808740A (en) * | 2006-06-09 | 2008-02-16 | Wyeth Corp | Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof |
TW200808741A (en) * | 2006-06-09 | 2008-02-16 | Wyeth Corp | 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts |
CL2007003410A1 (es) * | 2006-11-28 | 2008-04-11 | Wyeth Corp | Compuestos derivados de 5-fluoro-8-{4-[4-(6-metoxiquinolin-8-il)piperazin-1-il]piperidin-1-il}quinolina; procedimiento de preparacion; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de trast |
TW200901974A (en) * | 2007-01-16 | 2009-01-16 | Wyeth Corp | Compounds, compositions, and methods of making and using them |
WO2010137018A1 (en) | 2009-05-27 | 2010-12-02 | Atir Holding S.A. | Piperazine, piperidine and tetrahydropyridine derivatives and their pharmaceutical use |
DK2445502T4 (da) | 2009-06-25 | 2022-11-28 | Alkermes Pharma Ireland Ltd | Heterocycliske forbindelser til behandling af neurologiske og psykologiske lidelser |
CA2937222C (en) | 2009-06-25 | 2019-06-04 | Alkermes Pharma Ireland Limited | Prodrugs of nh-acidic compounds |
AU2011270701B2 (en) | 2010-06-24 | 2015-05-14 | Alkermes Pharma Ireland Limited | Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
HUE065359T2 (hu) | 2011-03-18 | 2024-05-28 | Alkermes Pharma Ireland Ltd | Szorbitán-észtereket tartalmazó gyógyászati készítmények |
GB201112987D0 (en) * | 2011-07-28 | 2011-09-14 | Ge Healthcare Ltd | Novel compound |
JP5952912B2 (ja) | 2011-12-15 | 2016-07-13 | アルカーメス ファーマ アイルランド リミテッド | 二級アミン化合物のプロドラッグ |
CA2867123C (en) | 2012-03-19 | 2021-02-16 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising water-insoluble antipsychotic agents and glycerol esters |
WO2013142205A1 (en) | 2012-03-19 | 2013-09-26 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising benzyl alcohol |
CA2867121C (en) | 2012-03-19 | 2021-05-25 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty acid esters |
US9193685B2 (en) | 2012-09-19 | 2015-11-24 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
CN103864761B (zh) * | 2014-03-12 | 2016-01-20 | 天津药物研究院有限公司 | 一种含吡啶的哌嗪类衍生物及其制备方法和用途 |
CN110368360A (zh) | 2014-03-20 | 2019-10-25 | 奥克梅斯制药爱尔兰有限公司 | 具有增加的注射速度的阿立哌唑制剂 |
KR101556571B1 (ko) | 2014-03-31 | 2015-10-01 | (주)월드트렌드 | 장식용 보석을 체결할 수 있는 안경 |
CA2964276A1 (en) | 2014-11-05 | 2016-05-12 | Flexus Biosciences, Inc. | Immunoregulatory agents |
UY36390A (es) * | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
MA41168A (fr) * | 2014-12-17 | 2017-10-24 | Acraf | Nouveaux composés antibactériens |
HUE049547T2 (hu) * | 2016-06-08 | 2020-10-28 | Acraf | Új baktériumellenes szerek |
CN112423754A (zh) | 2018-03-05 | 2021-02-26 | 奥克梅斯制药爱尔兰有限公司 | 阿立哌唑的给药策略 |
KR20210076226A (ko) | 2019-12-13 | 2021-06-24 | 주식회사 에피바이오텍 | 피페라진 유도체를 포함하는 탈모의 예방 또는 치료용 조성물 |
WO2023144764A1 (en) | 2022-01-29 | 2023-08-03 | Suven Life Sciences Limited | Benzoisothiazole and benzoisoxazole compounds for the treatment of mental disorders |
CN117003693A (zh) * | 2022-05-05 | 2023-11-07 | 四川大学华西医院 | 一类哌啶衍生物及其制备方法和用途 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1279843A (en) * | 1969-05-23 | 1972-06-28 | Science Union & Cie | Benzamidoethyl-piperazines and process for their preparation |
US4684651A (en) * | 1981-03-17 | 1987-08-04 | Mitsubishi Chemical Industries Limited | Alkylenedioxybenzene and acid addition salts thereof useful as hypotensives |
JPS58154573A (ja) * | 1982-03-09 | 1983-09-14 | Mitsubishi Chem Ind Ltd | アルキレンジオキシベンゼン誘導体及びその酸付加塩 |
JPS5910517A (ja) * | 1982-07-09 | 1984-01-20 | Mitsubishi Chem Ind Ltd | 血圧降下剤 |
AR241161A1 (es) * | 1984-07-30 | 1991-12-30 | Merrelll Dow Pharmaceuticals I | "procedimiento para la preparacion de derivados n-aminoalquilen sustituidos de la glutarimida" |
US5010078A (en) * | 1988-05-24 | 1991-04-23 | American Home Products Corporation | Aryl- and heteroaryl piperazinyl carboxamides having central nervous system activity |
EP0367888A1 (en) * | 1988-11-08 | 1990-05-16 | ISTITUTO LUSO FARMACO D'ITALIA S.p.A. | 2,2-Disubstituted 2,3-dihydro-1,4-benzodioxin derivatives having hypotensive activity |
DK611489A (da) * | 1988-12-08 | 1990-06-09 | Duphar Int Res | Anxiolytisk aktive piperazinderivater og farmaceutiske praeparater med indhold af saadanne forbindelser |
GB8909209D0 (en) * | 1989-04-22 | 1989-06-07 | Wyeth John & Brother Ltd | Piperazine derivatives |
US5112824A (en) * | 1989-12-08 | 1992-05-12 | Merck & Co., Inc. | Benzofuran compounds as class III antiarrhythmic agents |
IE911774A1 (en) * | 1990-06-11 | 1991-12-18 | Akzo Nv | Pyridinylpiperazine derivatives |
AU645681B2 (en) * | 1991-05-02 | 1994-01-20 | John Wyeth & Brother Limited | Piperazine derivatives |
GB9411099D0 (en) * | 1994-06-03 | 1994-07-27 | Wyeth John & Brother Ltd | Piperazine derivatives |
-
1992
- 1992-04-29 AU AU15241/92A patent/AU645681B2/en not_active Ceased
- 1992-04-29 MX MX9201991A patent/MX9201991A/es active IP Right Grant
- 1992-04-29 IL IL10172292A patent/IL101722A/en active IP Right Grant
- 1992-04-30 AT AT92303918T patent/ATE115566T1/de not_active IP Right Cessation
- 1992-04-30 DE DE69200893T patent/DE69200893T2/de not_active Expired - Lifetime
- 1992-04-30 ES ES92303918T patent/ES2065133T3/es not_active Expired - Lifetime
- 1992-04-30 HU HU9201462A patent/HU223527B1/hu not_active IP Right Cessation
- 1992-04-30 MY MYPI92000746A patent/MY107756A/en unknown
- 1992-04-30 FI FI921942A patent/FI108720B/fi active
- 1992-04-30 EP EP92303918A patent/EP0512755B1/en not_active Expired - Lifetime
- 1992-04-30 GB GB9209340A patent/GB2255337B/en not_active Expired - Fee Related
- 1992-04-30 BR BR929201624A patent/BR9201624A/pt not_active Application Discontinuation
- 1992-04-30 RU SU5011552/04A patent/RU2193561C2/ru active
- 1992-04-30 DK DK92303918.4T patent/DK0512755T3/da active
- 1992-05-01 CA CA002067929A patent/CA2067929C/en not_active Expired - Lifetime
- 1992-05-01 JP JP04112527A patent/JP3095521B2/ja not_active Expired - Fee Related
- 1992-05-02 KR KR1019920007528A patent/KR100203254B1/ko not_active IP Right Cessation
- 1992-05-02 CN CN92103153A patent/CN1040106C/zh not_active Expired - Fee Related
- 1992-05-04 SK SK1344-92A patent/SK280133B6/sk not_active IP Right Cessation
- 1992-05-04 CZ CS19921344A patent/CZ286778B6/cs not_active IP Right Cessation
- 1992-07-01 IE IE921409A patent/IE64634B1/en not_active IP Right Cessation
-
1993
- 1993-06-15 UA UA93002895A patent/UA39917C2/uk unknown
-
1995
- 1995-05-11 US US08/438,812 patent/US6127357A/en not_active Expired - Fee Related
- 1995-06-22 HU HU95P/P00338P patent/HU211148A9/hu unknown
-
1996
- 1996-12-06 CN CN96118586A patent/CN1084619C/zh not_active Expired - Fee Related
-
1998
- 1998-03-12 HK HK98102076A patent/HK1003001A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR920021522A (ko) | 피페라진 유도체 | |
KR930021624A (ko) | 피리미딘 유도체 및 이의 제조방법 | |
RU2386618C2 (ru) | Производные пиперазинилпиридина в качестве агентов против ожирения | |
JP2002534468A5 (ko) | ||
PE20030269A1 (es) | Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas | |
RU2003100518A (ru) | Производные бензотиазола | |
KR890005095A (ko) | 신규 화합물들 | |
RU2003121018A (ru) | Производные карбоксамида и их использование в лечении тромбоэмболических заболеваний и опухолей | |
ES2192394T3 (es) | Profarmacos de inhibidores de la bomba de protones. | |
PE20010482A1 (es) | Derivados de 3-ureido-pirazol y procedimiento para su preparacion | |
RU2009118602A (ru) | Производное индола | |
MY141597A (en) | 2,4-disubstituted thiazolyl derivatives | |
EA199800909A1 (ru) | Тригидрат мезилата 5-(2-(4-(1,2-бензизотиазол-3-ил)пиперазин-1-ил)этил)-6-хлор-1,3-дигидро-2н-индол-2-она, фармацевтическая композиция и способ лечения психического расстройства | |
KR870007154A (ko) | 4,5,6-치환-n-(치환페닐)-2-피리미딘아민, 그 제조방법 및 그 화합물이 들어 있는 조성물 | |
MY133108A (en) | Muscarinic antagonists | |
RU2003130635A (ru) | Применение производных n-фенил-2-пиримидинамина против основывающихся на мастоцитах заболевания, подобных аллергическим нарушениям | |
DE69522257T2 (de) | Piperidin-Derivate und diese enthaltende Antiplättchen-Agents | |
RU2003127392A (ru) | Комбинации, содержащие ингибитор трансдукции сигнала и производное эпотилона | |
RU2009148049A (ru) | Терапевтическое средство для лечения церебрального инфаркта | |
KR890001988A (ko) | 치환된 알켄카복실산아미드 및 이의유도체 | |
SE8600173L (sv) | Antipsykotiska cykliska imidderivat av 2-(4-butylpiperazin-1-yl)pyridiner s | |
KR970700646A (ko) | 니트록시기를 포함한 벤질아민 유도체, 및 심장 혈관 질환과 안압 상승의 치료를 위한 이의 용도(nitroxy group-containing benzylamine derivatives and their use for treating cardiovascular diseases, as well as increased intra-ocular pressure) | |
DK634589A (da) | Acyloxypropanolaminer og deres anvendelse | |
KR920008020A (ko) | 피레라진 유도체 | |
KR890014485A (ko) | 아실화 우레아 유도체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20080117 Year of fee payment: 10 |
|
LAPS | Lapse due to unpaid annual fee |